GlassScriptPhysician profile
Jennifer Erdman
NPI 1013222157
$5,700.33
in general payments reported to CMS, 2019-2025
20 companies · $1,547 in 2025
The $1,547 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $548 · 2022: $1,151 · 2023: $1,108 · 2024: $1,347 · 2025: $1,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,986 · Education: $16.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,986.05 |
| Education | $16.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,319.45 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $794.97 | 2021-2025 | Caplyta |
| Alkermes, INC. | $622.30 | 2021-2025 | Lybalvi, Aristada |
| Harmony Biosciences LLC | $566.06 | 2022-2025 | Wakix |
| Axsome Therapeutics, INC. | $398.00 | 2023-2025 | Auvelity |
| Lundbeck LLC | $316.86 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $264.35 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $254.36 | 2021-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $231.07 | 2024-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $205.79 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $196.60 | 2022-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $104.61 | 2021-2023 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $101.21 | 2021-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $76.61 | 2022-2024 | Jornay Pm |
| Corium, LLC | $58.93 | 2023 | Azstarys, Azstarys |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $55.46 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $44.09 | 2022-2023 | Belsomra |
| Collegium Pharmaceutical, INC. | $41.48 | 2025 | Jornay Pm |
| Eisai INC. | $26.80 | 2021 | |
| Jazz Pharmaceuticals INC. | $21.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Erdman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.